A growing body of evidence shows that SIRT3 inhibits tumorigenesis by deacetylation of its substrates in HCC mitochondria, pointing to SIRT3 as a potential therapeutic target [28]. The gene discussed is SIRT3; the disease is hepatocellular carcinoma.